header logo image


Page 48«..1020..47484950..6070..»

Archive for the ‘Biotechnology’ Category

Biotechnology remains a mystery for many Canadians – Western Producer

Saturday, June 24th, 2017

Canadians generally do not have a solid understanding of what exactly the term biotechnology refers to, according to recently released public opinion research collected by Nielsen Consumer Insights on behalf of Agriculture Canada.

In July 2016, the department issued a contract asking Nielsen Consumer Insights to conduct a comprehensive research project to measure Canadian consumers perceptions and attitudes towards issues related to domestic agriculture and agri-food.

The research would help provide insight while developing the next agriculture policy framework, which comes into force in 2018. The data was collected via a series of focus groups, telephone calls and online consultations.

Overall, researchers found 88 percent of those surveyed have a generally positive or neutral view of biotechnology.

Canadians generally feel that biotechnology will have a positive impact on their future, placing it near the top of a selection of new and emerging technologies in terms of this promise, researchers told Agriculture Canada.

However, Canadian knowledge and view on specific forms of biotechnology varies widely.

Researchers found that most of the people who were surveyed struggled to give examples of biotechnology used in agriculture. Participants typically offered up examples used within the medical and health care fields, such as stem cells, antibiotics and robotics.

The association of the term biotechnology with health applications may be an indication that it is profiting from a halo effect, re-searchers warned.

This could lead to people feeling that biotechnology is positive because the applications that they associate with it promote human well-being.

Researchers reported an aversion to applications of biotechnology that consumers felt had the potential to upset the natural order or would allow scientists to play god.

The closer the application could be seen in terms of living, breathing organisms, the more resistance there was to the specific applications, such as genetically modified animals.

Researchers found less than half (46 percent) of the Canadians surveyed were familiar with the concept of GM animals, which has dropped from previous years.

Canadians werent particularly comfortable with the idea. Many within the focus groups raised moral or ethical concerns about it.

People were much more likely to see the potential risks of GM animals as outweighing the benefits than they were likely to see with other technologies, the report reads.

Those technologies include biofuel, gene editing and genetically modified fish, including fish that could be used to produce insulin for diabetic human patients.

Despite specific consumer concerns around certain applications, researchers found Canadians have not rejected biotechnology all together.

Consumer opinions are built based on the specific use presented and individual knowledge of that particular form of biotechnology, researchers said.

In other words, there does not appear to be a blanket approval or rejection of biotechnologies themselves.

Thats good news for Canadian agriculture, where participants stressed Canada could easily be-come a world leader in the agriculture and food biotechnology re-search field. That conviction, researchers found, is increasing as more attention is paid to it.

It is possible that this is due to the growing role that these technologies are playing in our food supply and a higher level of media attention, Agriculture Canada was told.

Similarly, people agree that these technologies will be developed elsewhere in the world where regulations and control may be less stringent, the report said, which isa situation Canadians said they would like to avoid. The federal government, respondents said, has an important role to play in the biotechnology field.

Over the course of the study, 875 Canadians were contacted last year by phone between Aug. 31 and Sept. 17 and Dec. 1-13. The phone portion of the research has a margin of error of plus or minus 3.3 percent.

Another 220 Canadians participated in the online survey, and 10 focus groups were held, with two meetings each in Toronto, Montreal, Vancouver, Halifax and Calgary.

Kelsey Johnson is a reporter with iPolitics, http://www.ipolitics.ca.

Originally posted here:
Biotechnology remains a mystery for many Canadians - Western Producer

Read More...

Play the iShares Nasdaq Biotechnology Index (ETF)’s (IBB) Popularity for Free – Investorplace.com

Saturday, June 24th, 2017

Wall Street is going gaga over the healthcare and biotech sector. The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) rallied 9% in four days. TheSPDR S&P Biotech (ETF) (NYSEARCA:XBI) rallied even more.

These are impressive moves that deserve respect. But I cannot chase it if I am not already on board the trade. Or I will end up buying someone elses profits. Wall Street loves to trade memes these days. A few weeks ago the IBB was dead money, now they cant have enough of it.

The hoopla centers around expectations from the new healthcare bill. I think we are giving it too much credit. We dont know if it will pass and even if it does, we dont know its full effects. But I am willing to bet that it wont be better to the sector than Obamacare was. This new bill is likely to be less, and therefore we could have a disappointment period coming.

Click to Enlarge Before you label me a perma-bear, I was a fan of the IBB a few weeks ago. Instead of chasing the momentum after it happens, a bit a good homework delivered great results. Case in point is this massive win from a bullish trade I shared on May 23 which yielded easy profits and out of thin air.

Now that everyone and their sister is chasing this rally in the IBB, I am ready to try and short it. Before you send out the posse to arrest me for daring to short the hot topic du jour, my trade is not against the sector, but rather is my bet against the short-term price action. I like to go long IBB on weakness but here I see the potential for a dip.

A lot of the enthusiasm is tied to politicians doing the right thing, and I am not so sure they will deliver. Even if they do, its probably going to take longer and be less than we expect. Eventually, traders will get antsy and lose interest and the IBB bids will abate, thereby creating a small vacuum below the current steep wedge. Therein lies the opportunity.

The Bearish Bet: Buy the IBB Aug $315/310 debit put spread for $1.50 or better per contract. If price falls through my spread in the next 56 days, I could triple my money. The faster and sooner the fall, the better otherwise time is my enemy.

To mitigate my out-of-pocket risk, I will leverage the value in the IBB ETF. I will sell longer dated puts to finance my bearish bet.

The Bank: Sell IBB Dec $270 puts and collect $5 per contract. This is a bullish trade which has a 90% theoretical chance of success. But if the IBB falls through my short put, then I will own the shares and could accrue losses below $265. But if Wall Street is correct about the political exuberance in the biotech sector, then I really have nothing to worry about. For a smaller risk profile, I could use a credit put spread instead.

Selling options is risky, so I never risk more than I am willing or able to lose.

Learn how to generate income from options here. Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

More here:
Play the iShares Nasdaq Biotechnology Index (ETF)'s (IBB) Popularity for Free - Investorplace.com

Read More...

Lilly Completes $90M Expansion of San Diego Biotechnology Center – Genetic Engineering & Biotechnology News

Friday, June 23rd, 2017

Eli Lilly has added a new state-of-the-art laboratory and 180,000 square feet of additional working space to its Biotechnology Center in San Diego, CA. Reporting completion of the $90-million expansion, Lilly said the 145% increase in working space will help to foster collaborations with external partners, and allow closer partnerships between its biotechnology, discovery chemistry, and research technology teams. The aim is to accelerate drug discovery within therapeutic areas including immunology, diabetes, oncology, neurodegeneration, and pain.

To further exploit its expertise in automated organic synthesis, and build on its Automated Synthesis Laboratory in Indianapolis, Lilly is also establishing the Lilly Life Science Studio at the San Diego site. The firm says the new facility will give researchers worldwide the ability to remotely test new ideas, and design, synthesize, and screen molecules.

"Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation, commented Jan Lundberg, Ph.D., executive vice president for science and technology and president of Lilly Research Laboratories. "Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years."

"This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market, added David A. Ricks, Lilly's chairman, president, and CEO. "This investment doesn't come without risk. America's biopharmaceutical leadership is driven by a free-market economy that rewards innovation. Today, there are multiple public policy threats to our business that would discourage or reduce our investment in the U.S. and the state. We are committed to working with policymakers and stakeholders to ensure our efforts to deliver new innovative medicines to patients are not threatened."

Lilly set up the San Diego Biotechnology Center, which is sited close to the University of California, San Diego, in 2009, having acquired Applied Molecular Evolution back in 2004.

Earlier this month Lilly reported that it will acquire a pipeline of dual amylin calcitonin receptor agonists (DACRAs) from KeyBiosciencefor the potential treatment of type 2 diabetes and other metabolic disorders.

Read more:
Lilly Completes $90M Expansion of San Diego Biotechnology Center - Genetic Engineering & Biotechnology News

Read More...

Roche’s lampalizumab halts geographic atrophy – European Biotechnology

Friday, June 23rd, 2017

A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trail US and German researchers showed efficacy in geographic atrophy, an advanced stage of AMD, which has currently no treatment.

One week prior to the publication, Roche announced it has intitiated two Phase III trails (CHROMA and SPECTRI) enroling 936 patients with the advanced form of AMD that affects 5 million AMD patients and has currently no cure. Primary endpoint is slowing for disease progression at 12 months, secondary endpoint is visual acuity at 24 months. However, rumors say the FDA could accelerate patient access through granting breakthrough status to the treatment.

In a multi-center, randomized, 18 month Phase study that recruited 129 AMD patients ( MAHALO), lead author Brian Yaspan observed a 20% reduction in lesion area progression in patients receiving Roche/Genentechs antibody drug candidate lampalizumab at acceptable safety profile. Lampalizumab zeroes in on complement D, part of the innate immune defenses alternative complement pathway

Genome analysis of participants identified a patient subgroup with complement D variants who showed a 44% reduction in geographic atrophy area progression. The authors say targeting the alternative complement pathway has potential to be a viable treatment option for patients with secondary geographic atrophy.

More:
Roche's lampalizumab halts geographic atrophy - European Biotechnology

Read More...

Shawnee Mission West High student wins international biotechnology competition – Kansas City Star

Friday, June 23rd, 2017

Kansas City Star
Shawnee Mission West High student wins international biotechnology competition
Kansas City Star
Hosted by the Biotechnology Institute, the competition challenges high school students from across the world to find solutions to health care, sustainability and environmental needs through biotechnology. Earlier this year, Smith was chosen along with ...

See the article here:
Shawnee Mission West High student wins international biotechnology competition - Kansas City Star

Read More...

Eli Lilly expands Biotechnology center – BSI bureau (press release)

Friday, June 23rd, 2017

The center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 per cent compared to the former facility.

Eli Lilly and Company has announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain.

The center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 per cent compared to the former facility. In addition to the center's established presence in preclinical and clinical immunology research, the new space allows for closer partnership between Lilly experts in biotechnology, discovery chemistry and research technologies while also fostering external collaborations.

As a pioneer in automated organic synthesis, Lilly is creating the Lilly Life Science Studio in San Diego. Building upon Lilly's Automated Synthesis Laboratory in Indianapolis, the new facility will allow researchers across the globe to remotely design, synthesize and screen investigational molecules in an unprecedented manner. Using the power of automation, the Lilly Life Sciences Studio will shape the next generation of drug discovery and expand the reach of individual scientists to test new ideas, while reducing the cost and minimizing the environmental impact of our research activities.

San Diego has long been an important location for Lilly. In 2004 Lilly acquired Applied Molecular Evolution, Inc. before establishing the Lilly San Diego Biotechnology Center in 2009, located near the University of California, San Diego, among other prominent biomedical research institutes. Since its establishment, the center has created more than 100 jobs with more than 200 scientists currently working in various research activities.

See the article here:
Eli Lilly expands Biotechnology center - BSI bureau (press release)

Read More...

Epigenetic drugs set to boost immunoncology – European Biotechnology

Friday, June 23rd, 2017

German oncologists have unveiled that market-approved inhibitors of DNA methyltransferases (DMNTi) and histone deacetylases (HDACi) act through expression of cancer neoantigens. They already have a biomarker test to identify responders.

The findings, reported in Nature Genetics, are good news for drug developers who want to broaden the scope of current immune checkpoint modulators through combination therapies that trigger cancer cells to release immunogenic neoantigens.

Following addition of epigenetic inhibitors to cancer cell cultures thousands of atypical transcripts with altered frameshift were expressed form previously ignored endogenous promotors of retroviral origin, resulting in profound tumour cell death, group leader Plass from German Cancer Centre told European Biotechnology. His team has already a biomarker assay that could identify responders to the treatment as it measures activation of the normally silent treatment induced, not-annotated transcription start sites (TINATs).

Up to now, pharma majors such as Roche/Genentech have largely relied on combination of their checkpoint inhibitors with personalised mRNA cancer vaccines. The new findings might open the avenue to a broader activation of cancer neoantigens than these vaccinesas over 2,500 TINATs have been identified in the human genome by the researchers. The retrotransposons (elements of human endogenous retroviruses, HERVs), which are located in long terminal repeats, have entered the human genome millions of years ago.

However, application of the findings might be hampered by the fact that TINATs, so far, have only been identified in the human genome, which might complicate preclinical in-vivo testing. Its unclear if they also exist in animals, says Plass, who is currently deciphering the exact mechanism that normally stops TINATs from being activated. First findings suggest that acetylation of transcription factors might play an important role.

See the original post:
Epigenetic drugs set to boost immunoncology - European Biotechnology

Read More...

Peterborough biotechnology startup targeting $50 million in equity financing – Kawartha Media Group

Friday, June 23rd, 2017

Kawartha Media Group
Peterborough biotechnology startup targeting $50 million in equity financing
Kawartha Media Group
Peterborough biotechnology startup targeting $50 million in equity financing. Community Jun 22, 2017 02:20 by Todd Vandonk Peterborough This Week. Share. Noblegen Inc. CEO and founder Adam Noble and CCO and co-founder Dr. Andressa Lacerda ...
Noblegen Announces the Opening of Its Second Round of Financing: Peterborough-based biotechnology startup ...ForexTV.com

all 4 news articles »

The rest is here:
Peterborough biotechnology startup targeting $50 million in equity financing - Kawartha Media Group

Read More...

Environmental Defense Fund: Sustainable farming, feeding growing population require biotechnology – Genetic Literacy Project

Wednesday, June 21st, 2017

It is critical that humanity meet the food needs of a growing population and relieve the increasing pressures on natural systems. Environmental Defense Fund supports the coexistence of diverse farming systems to ensure a sustainable future for farmers, society, and our environment. Achieving these goals will require a comprehensive strategy that draws on a wide range of approaches and technologies, including biotechnology.

EDF recognizes the use of biotechnology as a legitimate deployment of science in the search for effective solutions, and also recognizes that past deployment of some biotechnology products has caused legitimate concerns. For that reason, we will support or oppose specific biotechnology products or processes based on transparent assessments of their health, environmental, social, and economic risks and benefits.The risks and benefits of biotechnology products will often vary by organism, geography and other variables, and need to be assessed at relevant temporal and spatial scales.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Our position on biotechnology

More here:
Environmental Defense Fund: Sustainable farming, feeding growing population require biotechnology - Genetic Literacy Project

Read More...

Evotec invests in Facio Therapies – European Biotechnology – European Biotechnology

Wednesday, June 21st, 2017

Evotec and co-investors support Dutch Facio Therapies BV with 4.8m to push development of Dux4 inhibitors to treat facioscapulohumeral dystrophy (FSHD), one of the most common forms of muscular dystrophy.

With its investement alongside unnamed Australian and North American investors, Evotec enters the field of musculoskeletal diseases.

Currently there is no causative treatment for the muscle wasting disease that affects 700,000 people worldwide. In a patient cell-based screening, Evotec and Facio Therapies (Leiden) have already identified some FSHD candidate drugs, which block the overexpression of the DUX4 protein in skeletal muscle cells that causes muscle atrophy and oxidative stress, hallmarks of the disease. About 20% of people with FSHD end up in a wheelchair.

Facio announced it will use the proceeds to select pre-clinical lead candidates for further development. According to the NIH, the field of muscular dystrophies received US$80m in funding in 2017. One tenth of the amount has been channeled into FSHD research.

Some companies have already started clinical testing of candidate drugs for treating FSHD. aTyr Pharma, Inc. is in Phase I/IIa testing of the protein drug Resolaris in early onset FSHD. Acceleron Pharma, Inc. has recently started Phase II testing of ACE083, an inhibitor of proteins of the TGF-beta family.

Read the original post:
Evotec invests in Facio Therapies - European Biotechnology - European Biotechnology

Read More...

Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego – PR Newswire (press release)

Wednesday, June 21st, 2017

About Lilly's Biotechnology Center and the Company's Presence in San DiegoThe center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 percent compared to the former facility. In addition to the center's established presence in preclinical and clinical immunology research, the new space allows for closer partnership between Lilly experts in biotechnology, discovery chemistry and research technologies while also fostering external collaborations.

"Being in the San Diego area for the last 13 years has been a game changer for us, specifically in the arena of discovering medicines for hard-to-treat autoimmune conditions," said Thomas F. Bumol, Ph.D., senior vice president of biotechnology and immunology research at Lilly. "With compounds such as Taltz (ixekizumab) for psoriasis, we've not only provided patients with a new treatment option, but we've also moved the needle for advancing science."

As a pioneer in automated organic synthesis, Lilly is creating the Lilly Life Science Studio in San Diego. Building upon Lilly's Automated Synthesis Laboratory in Indianapolis, the new facility will allow researchers across the globe to remotely design, synthesize and screen investigational molecules in an unprecedented manner. Using the power of automation, the Lilly Life Sciences Studio will shape the next generation of drug discovery and expand the reach of individual scientists to test new ideas, while reducing the cost and minimizing the environmental impact of our research activities.

"Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation. Our expansion in San Diego is a prime example of investing in a research success story," said Jan Lundberg, Ph.D., executive vice president for science and technology and president of Lilly Research Laboratories. "Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years."

San Diego has long been an important location for Lilly. In 2004 Lilly acquired Applied Molecular Evolution, Inc. before establishing the Lilly San Diego Biotechnology Center in 2009, located near the University of California, San Diego, among other prominent biomedical research institutes. Since its establishment, the center has created more than 100 jobs with more than 200 scientists currently working in various research activities.

"Congratulations to Lilly on the expansion of its new Biotechnology Center, which will double its drug research and development in San Diego, create high-quality jobs, and encourage collaboration on groundbreaking therapies that improve patient care and lower costs," said Representative Scott Peters (D-CA 52nd Congressional District). "San Diego's life sciences industry is changing the face of medicine and companies like Lilly are driving this innovation."

About Lilly's U.S. Research and Development InvestmentNearly $250 million of Lilly's $850 million capital investments will be dedicated to supporting its research and development centers around the U.S., including the center in San Diego, in 2017. Lilly's other U.S. research centers are located in Indianapolis, Indiana; Cambridge, Massachusetts; New York, New York; and Philadelphia, Pennsylvania.

In 2017, Lilly plans to spend approximately $5 billion on global R&D, nearly $4 billion of which will be invested in U.S. based programs, including projects with many of California's leading biomedical research institutions.

"This investment doesn't come without risk. America's biopharmaceutical leadership is driven by a free-market economy that rewards innovation," said Ricks. "Today, there are multiple public policy threats to our business that would discourage or reduce our investment in the U.S. and the state. We are committed to working with policymakers and stakeholders to ensure our efforts to deliver new innovative medicines to patients are not threatened."

AboutEli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com and http://www.lilly.com/newsroom/social-channels. C-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of the Lilly Biotechnology Center in San Diego, California and other planned capital projects, and reflects Lilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the processes of pharmaceutical research and development, and capital project implementation and completion. Among other things, there can be no guarantee that the projects will be completed on the anticipated timeline or at all or that Lilly will realize the expected benefits of the projects. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements.

Nicole Hebert, hebert_nicole@lilly.com, (317) 701-9984 Jackie Shelton, sheltonj@lilly.com, (317) 719-5928

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eli-lilly-and-company-unveils-expanded-biotechnology-center-in-san-diego-300477395.html

SOURCE Eli Lilly and Company

http://www.lilly.com

Follow this link:
Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego - PR Newswire (press release)

Read More...

NICreL Seeks FG’s Support For NABDA To Boost Biotechnology … – Leadership Newspapers

Wednesday, June 21st, 2017

By Michael Oche, Abuja

The New Initiative for Credible Leadership, a leading research and development based Civil Society Organization in Nigeria has hailed the National Biotechnology Development Agency (NABDA) under the leadership of Professor Mrs. Lucy Ogbadu for her innovations in biotechnology and genetic engineering in the country.

NABDA is an organization aimed at promoting, coordinating, and setting research and development priority in biotechnology for Nigeria.

NICreL noted the ongoing economic quandary in Nigeria as a result of fall in oil prices calls for all stakeholders to put on their thinking cap for the country to move away from its over dependency and focus on other sectors, particularly agriculture which was the mainstream of the countrys gross national earnings was booming before the advent crude oil.

Addressing newsmen on the activities of Nigerias research institutions in Abuja, Reverend Steven Onwu, Executive Secretary of the Centre, averred that NABDA within the last two years has continued to work assiduously hard under its mandate to put the nation at par with global realities through its various innovations, scientific breakthroughs in the field of genetics and intellectual acumen to move the country forward.

Onwu noted that Professor Ogbadu is demonstrating to Nigerians through her sterling leadership anchored on accountability, probity and transparency that our journey to the promised land is not a mirage if we put all hands on deck and the country first in all our dealings.

His words, The organization is patriotically driving the change agenda by blazing the trail in this uncommon field and the agency deserves a better funding support to do more.

No country in the world is as naturally endowed as Nigeria in terms of 21st century resources that are scattered across the various locations in the country and would require the needed intellectual drivers to achieve that amount of greatness which is commensurate with our resources.

The NICreL executive, while calling on the Nigerian Government to support the Ogbadu-led NABDA, noted that the agency needed more encouragement to continue to promote biotechnology activities that positively respond to national aspirations on food security, job/wealth creation, affordable healthcare delivery and sustainable environment.

See the rest here:
NICreL Seeks FG's Support For NABDA To Boost Biotechnology ... - Leadership Newspapers

Read More...

On eve of biotech’s big convention, Biotechnology Innovation … – San Francisco Business Times

Monday, June 19th, 2017
On eve of biotech's big convention, Biotechnology Innovation ...
San Francisco Business Times
Ahead of the Biotechnology Innovation Organization's annual convention in San Diego, we talk to Jim Greenwood, the president and CEO of the industry trade ...
The BIO International Convention Kicks Off Four Days of ...Business Wire (press release)

all 3 news articles »

Read the original:
On eve of biotech's big convention, Biotechnology Innovation ... - San Francisco Business Times

Read More...

Biotechnology could spur Africa’s industrialisation – Southern Times Africa

Monday, June 19th, 2017

Sifelani Tsiko recently in Lilongwe, Malawi

An industrial development strategy could be built on the back of Africas agricultural sector underpinned by the adoption of new and emerging technologies such as biotechnology to support improved yields, value addition and services that feed into the whole agro-processing value chain, a top Common Market for Eastern and Southern Africa (COMESA) official says.

Getachew Belay, a senior biotechnology policy advisor told Zimpapers Syndication recently on the sidelines of a communication training workshop for journalists on biotechnology and biosafety, that the adoption of genetically modified cotton developed using a bacterium Bacillus thuringiensis (Bt) which naturally produces a chemical harmful only to a small fraction of insects such as the bollworm, could increase yields and enhance competitiveness.

He says cotton farmers in Africa suffer huge losses due to pest problems.

The most destructive of pests is the African bollworm (Helicoverpa armigera), which can cause severe losses of up to 100 percent like we saw on some cotton fields in Salima here in Malawi, the Comesa biotech policy advisor says.

In unprotected fields pest damage can be very severe and when you look at Bt cotton crop on trial you can see hope that its possible for African farmers to increase their yields and competitiveness of their crop on the market.

Using Bt cotton developed using bacterium Bacillus thuringiensis, which naturally produces a chemical harmful only to a small fraction of insects such as the bollworm, experts say reduction in pest infestations can increase yields and improve the livelihoods of cotton growers.

The Bt toxin is inserted into cotton, causing cotton, called Bt cotton, to produce this natural insecticide in its tissues.

Biotechnology experts argue that cotton farmers in Zimbabwe, Malawi and most other African countries, can effectively reduce input costs and control damage from bollworms and other insects that frequently damage cotton by adopting Bt cotton.

For several decades, has lagged behind in terms of the industrial dynamism required to boost farmer earnings, employment, economic growth and competitiveness on the global market.

But in recent years, there is a growing realisation of the importance of industrialisation.

In 2016, the UNs Economic Commission for Africa (UNECA) published a major report on industrialization in Africa where it asserts that structural transformation in Africas economies remains the highest priority and industrialization is the top strategy for achieving it in practice.

And, Belay says, biotechnology is one of the major tools for achieving industrialisation.

Im convinced that biotechnology has many opportunities to drive Africas industrialisation, he says.

We have Bt cotton, Bt maize and soya and biotechnology can enhance the competitiveness of our crops and agricultural products especially when it comes to value addition and beneficiation as it was stipulated in our African industrialisation agenda.

Already we are seeing the benefits of adopting biotech crops in South Africa. Livestock feed sectors in Zambia and even Zimbabwe cannot compete with SAs GM stock feed which is produced cheaply. We need to adopt this new technology to cut costs.

Europe relies heavily on GM soya for its livestock feed industry and this has enhanced its competitiveness.

Africa has a low uptake of biotech food crops due to lack of awareness and stiff resistance, scientists say.

International Service for the Acquisition of Agri-Biotech Applications (ISAAA) AfriCenter director Margaret Karembu told journalists at the workshop that adoption of agricultural biotechnology has lagged behind compared to the rapid rates seen in the medical and health sectors.

Where are we as Africans? This is the question, we need to think seriously about the good work (on agricultural biotechnology) going on in our labs, she said. What is our place in the global biotechnology space? We need reclaim it and improve the livelihoods of our farmers across the continent.

Karembu said lack of awareness and a constrained regulatory environment had also slowed down the uptake of agricultural biotechnology.

Lack of awareness of the benefits and the regulatory framework has affected the tide towards the adoption of biotechnology. The victim mentality has been largely to blame for this.

We think of ourselves as victims of the technology. The fact is that our public institutions and universities have been doing research on biotech crops for years and this has not moved to the commercialization stage, she says. She says Africa needs to diffuse myths and misconceptions around GMO crops.

The media has a big role to play in clearing some of the misconceptions about biotechnology and GMOs, the ISAAA director says.

When media demonises the science, it becomes difficult to correct the mistakes. There is a lot of unfamiliarity with the technology and having fixed mind sets will not help our struggling farmers.

The farmers you saw in Salima are poor and they are struggling. Why should we block them from accessing the Bt cotton varieties that can significantly boost their yields and income? Farming should not be for leisure, its a business and it should be there to improve the quality of livelihoods of the farmers.

Biotechnology is one of the tools we can use to first of all improve crop yields and secondly to support Africas industrialisation goals for value addition and beneficiation.

Karembu urged the media to encourage dialogue and to correct misinformation.

The information we generate should be guided by credible scientific evidence and not unverified Google information, she says. If you have a headache people just Google and Google has become the answer. The world is polluted by a lot of unsubstantiated facts. We need to change the narrative and challenge the myth that Africa enjoys being poor the romanticisation of poverty.

Stringent and expensive regulatory process in Africa has slowed down uptake of biotechnology crops.

Biotech experts say the regulatory process is burdensome and makes everything unpredictable while in some African countries there is fear of change and challenging of the status quo when it comes to biotechnology.

According to ISAAA, the production of biotech crops increased 110-fold from 1996 with countries now growing the crops on 2,1 billion hectares worldwide.

The global value of the biotech seed market alone was US$15,8 billion in 2016. A total of 26 countries, 19 developing and 7 industrial grew biotech crops.

By 2016, at least four countries in Africa had in the past placed a GM crop on the market. These included Egypt, South Africa, Burkina Faso and Sudan.

But due to some temporary setback in Burkina Faso and Egypt, only South Africa and Sudan planted biotech crops on 2,8 million hectares

South Africa is one of the top 10 countries planting more than one million hectares in 2016 and continued to lead the adoption of biotech crops on the African continent.

Kenya, Malawi and Nigeria have transitioned from research to granting environmental release approvals while six others Burkina Faso, Ethiopia, Ghana, Nigeria, Swaziland and Uganda made significant progress towards completion of multi-location trials in readiness for considering commercial approval, ISAAA reported.

But the road to the adoption of Bt cotton technologies in Africa still faces stiff resistance.

Supporters of GM crops have to grapple with vocal anti-GMO activists, limited capacity to deal with the processing of GM research applications, bureaucratic delays in approving field trials, mistrust and resistance from key decision makers in Government and limited public awareness of the issues surrounding research and development of GM crops.

In addition, they have to contend with issues related to disease resistance, bottlenecks encountered when co-ordinating with other line ministries, trade-related restrictions, biosafety regulation and the overwhelming influence of multinational companies, Governments and their sidekicks NGOs. And, despite the threats, biotechnology experts say benefits from the biotech agro-linked industrial development outweigh the threats.

SADC drew up its Industrialisation Strategy and Roadmap which seeks to speed up industrialisation by strengthening the comparative and competitive advantages of the economies of the region.

The strategy which covers the period 2015 2063 is anchored on three pillars industrialisation, competitiveness and regional industrialisation.

The whole industrialisation agenda aims to help SADC member states to achieve high levels of economic growth, competitiveness, incomes and employment.

To access the funds, SADC countries have set up committees made up of government and private sector players to identify priority areas for funding.

At regional level, three areas have been prioritised, namely agro processing, mining and downstream processing.

For all this, biotechnology could be a useful tool to drive the regions industrialisation agenda, Belay says.

Its not a silver bullet, but its one of the many tools we can use to drive the continents industrialisation strategy. Agriculture is fundamental to Comesa member states in terms of improving food and nutrition security, increasing rural income, employment and contributions to GDP and expert earnings.

We need to explore ways of enhancing the use of biotechnology to drive industrialisation and improved livelihoods for farmers in Africa.

Analysts say Africa badly needs increased investment in infrastructure of all kinds reliable clean energy and water systems, medical clinics, technical colleges, railways, roads, bridges, fiber optic networks, and factories of many kinds.

Industrialisation can benefit the expansion of intra-African trade by supporting a more diversified export economy, wrote an economic analyst.

In particular, the development of rural and food processing industries could help to lift significant numbers from poverty. But, to facilitate trade in goods and services, it is essential to reduce distribution costs by improving and expanding road, rail and other communication infrastructure. -Zimpapers Syndication

See the article here:
Biotechnology could spur Africa's industrialisation - Southern Times Africa

Read More...

Opinion: Three must-own cancer stocks for your biotechnology portfolio – MarketWatch

Monday, June 19th, 2017

June should be national cancer month.

Each year around this time, oncology groups and Wall Street brokerages hold a rash of conferences where researchers reveal the latest, greatest potential cancer cures.

This year has been no exception. Above all, we learned about remarkable advances in two exciting cancer therapies and three great companies that will benefit.

Heres more detail. (Ive kept the technical language to a minimum.)

Tumors are smart. They know how to trick the immune system into missing them. But scientists are wising up to their tricks. In one evasive strategy, tumors release an enzyme that renders them invisible. If you block the enzyme, your immune system can find tumors and destroy them with the help from cancer drugs. This is the key to an early-stage cancer weapon you should invest in, known as IDO inhibitors.

IDO stands for Indoleamine 2,3-dioxygenase, an enzyme released by tumors to blind the bodys immune system. IDO is a strange drug target, because IDO inhibition by itself has no noticeable anti-cancer effect, says Tanguy Seiwert, a cancer-therapy researcher and medical doctor who teaches at the University of Chicago. Suppressing IDO, however, makes tumors vulnerable.

The best pure play in IDO inhibitors is a company whose shares I own, and have suggested since December 2011 in my stock newsletter, Brush Up on Stocks. Were up 750% in this company since 2011 ($14 to $120). But I think this stock is still a hold because there are bigger gains ahead.

Incyte Corp. INCY, +3.58% just released excellent data on its IDO inhibitor, called epacadostat, at the American Society of Clinical Oncology (ASCO) conference. In combination with cancer therapies from Merck & Co. MRK, +1.13% and Bristol-Myers Squibb Co. BMY, +1.40% it showed excellent results against several kinds of cancer.

It looks really good. I think this was a coming-out party for IDO inhibitors, says Seiwert. Besides effectiveness, one of the main positives is that epacadostat is safe. This means it can be readily used to assist many other cancer drugs. You can add it to a ton of things because the cost is low, in terms of toxicity.

Incyte is an ideal biotech company for investors because it is self-funding. It has a very profitable drug called Jakafi, for a rare blood disorder, which supports research on new drugs like the IDO inhibitor. So investors dodge dilutive financings.

So why hasnt Incytes stock shot up? Investors have three main worries. But they look like false fears.

One bit of fake news circulating is that Incyte showed success, in part, only because it omitted patients from some results, which drove up the percentage of success stories. But this is a dubious critique for two reasons. Even if you included the three patients left out, it would only lower the success rate by a few percentage points, notes J.P. Morgan analyst Cory Kasimov. Second, Incyte offered several separate data sets showing success in many types of cancer, but the omission only affected one subgroup, says Seiwert. I think this was way overblown.

The next fear: Competitor NewLink Genetics Corp. NLNK, +3.27% recently announced Roche AG RHHBY, +0.21% handed back development rights to its IDO, following lousy results in a Roche study. Some investors take this as a sign that IDO is malarkey. But William Blair analyst Katherine Xu thinks this is bullish for Incyte, since it signals a competitor may be gone. NewLinks IDO may have fared poorly because it works differently than Incytes IDO, or because Roche used an extremely sick patient population. Neither scenario reflects poorly on Incyte.

The third knock on Incyte is the one to watch. While Seiwert is impressed with Incytes IDO results, he points out the Phase II results are early-stage, and longer-term studies are needed to learn more about patient survival. Those studies are in the works. Incyte has nine Phase III studies planned with Merck and Bristol-Myers Squibb, says Xu. The outcomes here are key, since about $50 worth of the current $120 Incyte stock price is linked to IDO.

In another key advance in cancer therapy in the past two years, doctors have learned how to extract a patients blood and genetically tweak white blood cells so they override evasive tactics used by tumors.

Then the cells are reproduced in a lab to expand the supply, and put back in the patients body so they can move in for the kill. Hopefully, the cells then continue to proliferate and thrive and stay on hand to fight any more cancer that comes along.

Known as chimeric antigen receptor T-cell therapy (CAR-T), this approach has produced remarkable results against blood cancers in patients who otherwise had almost no hope of survival. CAR-T works by unblocking cancer cell receptors normally sought out by the immune system.

This is one of the most exciting therapies in immunotherapy, said Jae Park, a Memorial Sloan Kettering Cancer Center cancer researcher and medical doctor, at the Jefferies 2017 Global Healthcare Conference in early June.

Probably the best pure play here is Kite Pharma Inc. KITE, +1.64% At the Jefferies conference, Kite CEO Arie Belldegrun showed images of a patients body riddled with tumors, which disappeared about a month after treatment began. The patient showed no sign of the disease a year later.

Kite has a product coming on the market by the end of this year, and probably many more on the way, says Brad Loncar, the cancer research expert behind the Loncar Cancer Immunotherapy CNCR, +2.93% exchange traded fund. This is pretty good progress for a therapy that was considered science fiction two years ago.

I suggested Kite in my stock letter at around $71 on May 17, and I think its still a hold even though it has already risen to $87, because this promises to be a blockbuster therapy. At the time, insiders were big buyers as the stock sold off on news of the death of a patient in one of its studies.

That unfortunate death highlights one of the key risks here. CAR-T patients have died because the therapy can cause brain swelling. Doctors are getting better at staving off adverse side effects, says Park. But they still dont fully understand what causes them, which should raise a yellow flag for investors.

Kite also faces competition from other companies developing CAR-T, including power players like Novartis AG NVS, +0.75% Pfizer Inc. PFE, +0.76% Johnson & Johnson JNJ, -0.21% and GlaxoSmithKline PLC GSK, -0.09% as well as Juno Therapeutics Inc. JUNO, +3.91% Cellectis SA CLLS, +0.00% Adaptimmune Therapeutics PLC ADAP, -0.44% and two privately held companies called Poseida Therapeutics and Nanjing Legend Biotech.

Any of these efforts may pan out nicely, but my pick as a third CAR-T play is bluebird bio BLUE, +3.59% which is partnering with Celgene Corp. CELG, +2.29% Bluebird just announced really impressive results for its CAR-T candidate called bb2121. In early studies, just released at ASCO, this therapy produced an overall response rate of 90% to 100% among hospice-type patients whose cancer was so bad that seven different attempts to cure them, on average, had failed.

To generate efficacy data on this level with an overall very tolerable safety profile is highly impressive, says Kasimov, at J.P. Morgan. With more key updates to come in 2017, we would continue to add to positions in bluebird bio.

At the time of publication, Michael Brush held INCY. Brush has suggested INCY and KITE in his stock newsletter Brush Up on Stocks. Brush is a Manhattan-based financial writer who has covered business for the New York Times and The Economist group, and he attended Columbia Business School in the Knight-Bagehot program.

Continued here:
Opinion: Three must-own cancer stocks for your biotechnology portfolio - MarketWatch

Read More...

Trumann student starting ABI biotechnology research internship – Democrat Tribune

Monday, June 19th, 2017

Dustin Rhoads of Trumann is participating in Biotechnology Research Internship at Arkansas Biosciences Institute. (Photo provided)

Five Arkansas State University students are pursuing their interest in science this summer through the Biotechnology Research Internship Program at the Arkansas Biosciences Institute (ABI) facility on campus. One of those students, Dustin Rhoads, is from Trumann.

The program provides basic support for A-State undergraduate science majors who want research experience in life sciences or applications of life sciences during the summer of their sophomore or junior years.

Each student is matched with a faculty mentor who is conducting research related to biotechnology or biology from one of several departments and colleges, based largely on the student's interests. Selection also is based on academic credentials.

The students, along with their future plans and comments from their applications are:

Dustin Rhoads plans to go to dental school after completing his degree at A-State. His faculty mentor also is Dr. Malathi Srivatsan.

"I chose to apply for this internship mostly because of my interest in the field," Rhoads said. "Neurology has always been and interest of mine. Furthermore, the research we are doing at Dr. Srivatsan's Lab could be used to help so many people. Neuroregeneration could impact the lives of millions, and to be a part of something that could do that is very special to me. What sparked my interest in science was the way it's completely unique from all other academic fields, it has no sense of complacency, and is forever evolving. Im the kind of person who would rather study how things work as opposed to memorizing hard set facts, so the sciences are definitely for me regarding that aspect. I chose Arkansas State University because growing up I was always around it, almost developing it as a second home before even leaving high school, also accompanied with the report of its programs, made it a complete match for me."

The other students are Madalyn Rose Weiner of Little Rock, Oliver Dozier of Paragould, Kayleigh Nelson of Marion, and Aylin Villalpa-Arroyo of Hidalgo, Mexico.

Each internship is valued at $2,500. The students work 20 hours per week for 10 weeks. An additional $500 is provided to the supporting laboratory for research supplies.

See more here:
Trumann student starting ABI biotechnology research internship - Democrat Tribune

Read More...

Nerium Biotechnology Issues Shareholder Letter and Commences Selling NeriumAD Advanced in Mexico – Marketwired (press release)

Sunday, June 18th, 2017

SAN ANTONIO, TEXAS--(Marketwired - June 15, 2017) - Nerium Biotechnology, Inc. ("Nerium" or the "Company") today announces that it is mailing a letter to shareholders in advance of the Company's annual meeting on June 29, 2017. The shareholder letter which is reproduced below, provides important information for shareholder consideration regarding the election of directors at the annual meeting. This is an important meeting for shareholders as the decisions made with respect to the election of the Company's board of directors will determine Nerium's future.

Nerium is pleased to confirm the support of its largest shareholders for the re-election of the current board of directors (the "Board"). The shareholder letter, as well as a letter received by Nerium from Crandell Addington, a large shareholder of Nerium and CEO, Chairman and Director of Phoenix Biotechnology, will be mailed to shareholders today. A copy of the shareholder letter and other materials is available on the Company's issuer profile on SEDAR and on the Company's website http://www.nbiinvestors.com.

Your Board needs your support, please vote using only the GREEN proxy FOR Dennis R. Knocke, Gustavo A. Ulloa, Jr., Richard J.G. Boxer, Michael Burke, Kerry Mitchell and Peter A. Leininger, M.D.

Shareholders are encouraged to vote via the internet at http://www.voteproxyonline.com and enter the 12 digit control number located on your GREEN proxy, to ensure your vote is received in advance of the proxy deadline of June 27, 2017 10:00 a.m. (Toronto time). Shareholders may also vote by sending their signed GREEN proxy to TSX Trust Company via fax: 416-595-9593 or email: tmxeproxysupport@tmx.com or by mail in the envelope provided.

The Company also announces that it has commenced selling its over-the-counter product, NeriumAD Advanced, in Mexico. This represents the effective development of a new distribution channel for the Company's products and a source of future revenue that does not depend upon the cooperation of the Company's distributor, Nerium International LLC (the "Distributor").

It has come to the Company's attention that the amount of the Distributor's sales in 2015 and 2016 were incorrect in the Company's June 2, 2017 management information circular (the "Circular"). The Company received multiple versions of the Distributor's 2015 financial statements, each containing different numbers. The Company mistakenly included as the amount of the Distributor's 2015 sales an amount provided in an earlier version of the Distributor's 2015 financial statements and included the amount from a later version of the Distributor's 2015 financial statements as the 2016 sales amount. In fact, the Distributor's 2015 sales were US$496,838,912. The Company has never received a final version of the Distributor's financial statements for 2016, but based on a draft version of the Distributor's 2016 financial statement, the Distributor's 2016 sales were US$336,331,483. Corrected versions of the tables included on pages 19 and 20 of the Circular are provided below. The Company does not believe the updated information changes in any material respect the issues raised by it in the Circular.

Year

In response to the group of dissident shareholders retaining a proxy solicitation agent in connection with the Company's upcoming annual meeting, the Company has retained Shorecrest Group to act as proxy solicitation agent on behalf of the Company for a fee of approximately US$75,000 and reimbursement of its reasonable out-of-pocket expenses. All costs of solicitation by management will be borne by the Company.

YOUR VOTE IS IMPORTANT. To support your current Board, please vote using only your GREEN proxy. Please disregard any other proxy received. If you have already voted using the dissident proxy and wish to vote FOR the current directors, please vote using the GREEN proxy sent to you. This will automatically revoke any previous proxies submitted. If you have any questions or require assistance in voting, please contact the proxy solicitation agent Shorecrest Group toll free at 1-888-637-5789 or direct 647-931-7454.

About Nerium Biotechnology, Inc.

Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company's shares are not listed on any stock exchange or quotation system.

Forward Looking Statements: Statements made in this press release that relate to future plans, expectations, events or performances, including with respect to the future distribution and sales of the Company's products and possible revenue, are forward looking statements. Forward-looking statements are not based on historic facts, but rather on current expectations regarding future events. They are based on information available to management and/or assumptions management believes are reasonable. Many factors could cause future events and outcomes to differ materially from those discussed in the forward-looking statements. Although the forward-looking statements are based on what management believes are reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof and, except as required by applicable securities laws, the Company does not assume any obligation to update or revise such forward-looking statements. More information about the Company is available in its disclosure documents, all of which are available on the Company's issuer profile on SEDAR at http://www.sedar.com

To view the shareholder letter and the letter received by Nerium from Crandell Addington please click the following link: http://media3.marketwire.com/docs/NeriumLetter.pdf

Read this article:
Nerium Biotechnology Issues Shareholder Letter and Commences Selling NeriumAD Advanced in Mexico - Marketwired (press release)

Read More...

$10M for birthplace of biotechnology – Innovators Magazine

Friday, June 16th, 2017

(CALIFORNIA)

Thebirthplace of biotechnology is to receive$10 million for a pioneering precision medicine programme.

It was announced this week thatthe California Initiative to Advance Precision Medicine (CIAPM) has been awarded the money from the local governments budget, a decision welcomed by theCalifornia Life Sciences Association (CLSA).

Sara Radcliffe, President & CEO, CLSA, said:California Life Sciences Association (CLSA) applauds Governor Jerry Brown, California State Senate and California Assembly leaders for their strong support of life sciences innovation, as demonstrated again in this years 2017-2018 budget deal which allocates a $10 million investment in precision medicine research. California is the birthplace of biotechnology and today the states life sciences sector employs over 287,200 people working to develop innovative new medicines, technologies and therapies needed to treat and cure patients.

The Californian city of San Diego ishostingtheBIO International Conventionalthe global event for biotechnology next week. It will celebrate the industrys many breakthroughs and on going impact on society.It will take place at the San Diego Convention Center between 19 and 22 June.

BIO International ConventionalCalifornia Initiative to Advance Precision Medicine

Visit link:
$10M for birthplace of biotechnology - Innovators Magazine

Read More...

ASA Provides Input to USDA, FDA on Advances in Biotechnology – KTIC

Friday, June 16th, 2017

The American Soybean Association (ASA) submitted comments this week to both the U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) regarding regulations in response to advances in genetic engineering.

ASA included in comments to USDA, that biotechnology is an essential tool in farmers quest to produce enough food to meet the needs of 9.7 billion people by 2050, creating the need for a clear, science-based regulatory system in the U.S. as an example and standard for regulatory systems of biotechnology internationally.

While applauding USDAs efforts to reduce the burden on regulated entities, ASA expressed concern that aspects of the rule as proposed will increase the regulatory burden and stifle research and innovation.

Additionally, ASAs comments to FDA cheered USDAs proposal to exclude certain genome-editing techniques from requiring pre-market approvals because they are low risk and could be found in nature or achieved through traditional breeding methods.

ASA concluded its support saying, Technological advancements such as genome editing offer an additional tool to combat threats while also improving sustainability in production agriculture.

Full comments to USDA and FDA can be found here and here, respectively.

Read the original:
ASA Provides Input to USDA, FDA on Advances in Biotechnology - KTIC

Read More...

FBI says Chinese spying, theft of US agricultural biotechnology is ‘a growing threat’ – Genetic Literacy Project

Friday, June 16th, 2017

As a group of visiting scientists prepared to board a plane in Hawaii that would take them back home to China, U.S. customs agents found rice seeds in their luggage. Those seeds are likely to land at least one scientist in federal prison.

Agriculture today is a high-tech business, but as that technology has developed, so has the temptation to take shortcuts and steal trade secrets that could unlock huge profits. The FBI calls agricultural economic espionage a growing threat and some are worried that biotech piracy can spell big trouble for a dynamic and growing U.S. industry.

Had they succeeded in stealing the gene-spliced rice, the scientists may have been able to reverse-engineer it and ultimately undercut [US company] Ventrias market. [Ventria President and CEO Scott] Deeter says it could have driven his company out of business.

Where the commodity in question is grown in open fields, its sometimes difficult, [Jason] Griess [the assistant U.S. attorney for the Southern District of Iowa] says.

Theft of intellectual property costs the U.S. economy hundreds of billions of dollars each year, according to a recent report from the Commission on the Theft of American Intellectual Property, a Washington, D.C.-based ad-hoc panel formed to study intellectual property theft. China, the authors say, is the biggest offender.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Spies In The Field: As Farming Goes High-Tech, Espionage Threat Grows

Read more:
FBI says Chinese spying, theft of US agricultural biotechnology is 'a growing threat' - Genetic Literacy Project

Read More...

Page 48«..1020..47484950..6070..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick